Source-grounded facts extracted from Autolus Therapeutics plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Autolus Therapeutics plc reported first quarter ended March 31, 2026 results: revenue $26.2 million. Guidance reaffirmed.
“Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL)”
Autolus Therapeutics plc announced a restructuring with charges of total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs affecting all areas of the business (approximately 13% of the Company’s workforce).
“Item 2.05 Costs Associated with Exit or Disposal Activities. On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses. This plan will implement a reduction in force whereby the Company will eliminate approximately 13% of the Company’s workforce, inclusive of employee-related actions that began in the second half of 2025. The Company anticipates that it will complete the implementation of the plan by the third quarter of 2026. Affected employees will be offered separation benefits, including severance payments and, where applicable, temporary healthcare coverage assistance. The Company estimates that it will incur total expenses relating to the realignment of approximately $8 million, consisting of severance and termination-related costs. The Company expects to record a significant portion of these charges in the first half of 2026.”
Autolus Therapeutics plc engaged Ernst & Young LLP (US) as its auditor.
“On April 14, 2026, the Audit Committee approved the engagement of Ernst & Young LLP (US) (“EY US”) as its new independent registered public accounting firm.”
Autolus Therapeutics plc dismissed Ernst & Young LLP (UK) as its auditor.
“(a) Dismissal of Independent Registered Public Accounting Firm. On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”) dismissed Ernst & Young LLP (UK) (“EY UK”) as the Company’s independent registered public accounting firm.”
Autolus Therapeutics plc reported the quarter and full year ended December 31, 2025 results: revenue $23.3 million. Guidance reaffirmed.
“Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025”
Autolus Therapeutics plc entered into Master Service Agreement with AGC Biologics S.p.A. valued at EUR 25 million (effective 2026-01-21).
“On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A (“ AGC ”) for the manufacture and supply of lentiviral vector (the “ Agreement ”)”
Martin Murphy departed as Director at Autolus Therapeutics plc.
“On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.”
Joseph Anderson departed as Director at Autolus Therapeutics plc.
“On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.”
Rob Dolski was appointed as principal accounting officer at Autolus Therapeutics plc.
“On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.”
Andrew Mercieca resigned as Vice President of Finance and principal accounting officer at Autolus Therapeutics plc.
“On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.”
Autolus Therapeutics plc reported financial results for first quarter ended March 31, 2024.
“Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its operational and financial results for the first quarter ended March 31, 2024.”
Ravi Rao was appointed as Non-Executive Director at Autolus Therapeutics plc.
“appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.”
Michael Bonney was appointed as Chairman of the Board at Autolus Therapeutics plc.
“appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.”
John Johnson resigned as Chairman of the Board at Autolus Therapeutics plc.
“On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.”
Autolus Therapeutics plc reported that prior financial statements should not be relied upon.
“On March 15, 2024, the Audit Committee of the Company’s Board of Directors, upon the recommendation of the Company's management, and after discussion with the Company's independent registered public accounting firm, Ernst & Young LLP, concluded that the Company’s audited consolidated financial statements for the years ended December 31, 2022 and 2021, and the consolidated statements of operations for the quarterly periods in those years, as presented in the Company’s reports previously filed with the Securities and Exchange Commission (the “ SEC ”), should no longer be relied upon as a result of the foregoing error.”
Autolus Therapeutics plc reported financial results for the year ended December 31, 2023.
“On March 14, 2024, the Company held a conference call to discuss its financial results for the year ended December 31, 2023.”
Autolus Therapeutics plc reported financial results for the full year ended December 31, 2023.
“On March 14, 2024, Autolus Therapeutics plc (the “ Company ”) issued a press release announcing its recent business highlights and financial results for year ended December 31, 2023.”
Autolus Therapeutics plc entered into Underwriting Agreement with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein valued at $350 million (effective 2024-02-08).
“On February 8, 2024, Autolus Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein (the “ Underwriters ”), in connection with the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) by the Company of 58,333,336 American Depositary Shares (“ ADSs ”) representing 58,333,336 ordinary shares of the Company at an offering price of $6.00 per ADS. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $350 million.”
Autolus Therapeutics plc entered into License Agreement with BioNTech SE valued at up to $582 million (effective 2024-02-06).
“On February 6, 2024 (the “ Execution Date ”), Autolus Therapeutics plc (the “ registrant ”) and the registrant’s wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited (together, with the registrant, the “ Company ”) entered into a License and Option Agreement (the “ License Agreement ”) with BioNTech SE (“ BioNTech ”)”
Robert W. Azelby was appointed as Class II director at Autolus Therapeutics plc.
“appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.”
Elisabeth Leiderman was appointed as Director at Autolus Therapeutics plc.
“On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.”
Kapil Dhingra resigned as Director at Autolus Therapeutics plc.
“On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.